More tools:Markets·Screener·Research·Chat

Elutia Inc. Class A Common Stock (ELUT) Financial Statements

Elutia Inc. Class A Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00BRBB847
XNAS · usd
0.83▲ 0.01 (1.07%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.82
Day's Range0.80 – 0.95
52-Week Range0.50 – 2.04
Volume24.6K
Avg Volume53.1K
Share Statistics
Shares Outstanding
Employees26
ExchangeXNAS
Listed2020-10-08
Share count as of August 10, 2026
Loading Income Statement…
Key questions about Elutia Inc. Class A Common Stock (ELUT)
What is Elutia Inc. Class A Common Stock's Market Cap?
Elutia Inc. Class A Common Stock's Market Cap is $36.8M, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's Trailing P/E?
Elutia Inc. Class A Common Stock's Trailing P/E is 0.7×, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's Price / Sales?
Elutia Inc. Class A Common Stock's Price / Sales is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's Revenue (TTM)?
Elutia Inc. Class A Common Stock's Revenue (TTM) is $12.1M, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's Net Income (TTM)?
Elutia Inc. Class A Common Stock's Net Income (TTM) is $51.8M, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's EBITDA?
Elutia Inc. Class A Common Stock's EBITDA is -$24.4M, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's Diluted EPS (TTM)?
Elutia Inc. Class A Common Stock's Diluted EPS (TTM) is 1.17, based on as-reported figures from SEC (XBRL) filings.
What is Elutia Inc. Class A Common Stock's EBITDA Margin?
Elutia Inc. Class A Common Stock's EBITDA Margin is -200.8%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales
YoY growth-11.6%+5.5%+16.2%-9.3%
Cost of goods sold
Gross profit
% of revenue59.6%57.9%58.5%55.8%
Sales and marketing
General and administrative
Research and development
Litigation costs, net
Total operating expenses
% of revenue387.5%261.7%259.1%212.5%
Loss from operations
% of revenue-327.9%-203.9%-200.6%-156.7%
Interest income, net——
(Gain) loss on revaluation of warrant liability
Other (income) expense, net
Loss before provision for income taxes
Income tax expense
Net loss from continuing operations
Net loss
% of revenue-315.0%-239.9%2164.2%-116.4%
Net loss for dilutive earnings per share——
Net loss per share - basic (in dollar per share)
Net loss per share - diluted (in dollar per share)—